2nd Circ. Nixes $1.3B Asthma Drug Suit V. AstraZeneca

Law360, New York (June 24, 2011, 5:02 PM EDT) -- The Second Circuit on Friday affirmed a win for AstraZeneca AB in a $1.3 billion suit accusing it of breaking a contract to develop a pediatric asthma drug for a San Diego pharmaceutical company.

Verus Pharmaceuticals Inc.'s contract with AstraZeneca merely required it to try to get regulatory approval in the U.S. for a drug called budesonide — it did not require the defendant to succeed, a three-judge panel ruled.

The plaintiff has for two years tried in vain to convince courts that AstraZeneca illegally dumped...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.